Running Through Walls: Biotech’s Digital Transformation

Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven’s drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven’s collaboration with Khloe Kardashian for Nurtec’s launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.

  • Subscribe:

Want more? Here’s the latest on Running Through Walls.

Larry Hamann, co-founder, president, and CEO of Interdict Bio, speaks with Venrock Vice President Mariana Mihalusova about lessons learned from his career in drug discovery. Hamann delves into where his love for organic chemistry stems from and why inclusive environments are essential to building successful teams. He also speaks about the do’s and don'ts when structuring collaborations with big pharma, when a drug is “good enough” to move forward in development and new approaches he's excited for.
  1. The Balancing Act of Drug Discovery
  2. Bust the Liars Without Elevating the Liars
  3. Healthy Skepticism in Product Management
  4. Culture and Connection
  5. High Will Over High Skill

Running Through Walls: Navigating the IPO Process

Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider when choosing a bank and touch on common mistakes CEOs make while going through an IPO. Fenton also walks through the components of a recent successful IPO deal and provides his expectations for the biotech market in 2021. 

  • Subscribe:


Want more? Here’s the latest on Running Through Walls.

Larry Hamann, co-founder, president, and CEO of Interdict Bio, speaks with Venrock Vice President Mariana Mihalusova about lessons learned from his career in drug discovery. Hamann delves into where his love for organic chemistry stems from and why inclusive environments are essential to building successful teams. He also speaks about the do’s and don'ts when structuring collaborations with big pharma, when a drug is “good enough” to move forward in development and new approaches he's excited for.
  1. The Balancing Act of Drug Discovery
  2. Bust the Liars Without Elevating the Liars
  3. Healthy Skepticism in Product Management
  4. Culture and Connection
  5. High Will Over High Skill